Elective orthopaedic surgery for inhibitor patients
- 26 September 2003
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 9 (5) , 625-631
- https://doi.org/10.1046/j.1365-2516.2003.00803.x
Abstract
Summary. We report on a series of 108 elective orthopaedic surgical procedures. It includes 88 radiosynoviortheses and 20 major orthopaedic procedures, performed on 51 patients at nine centres worldwide. The average age of patients was 28.5 years (range 5–40 years), and the average follow‐up time was 2 years (range 1–5 years). There were 82 good results, 15 fair and 11 poor. In the synoviorthesis group (41 patients, 88 synoviortheses) the average age was 14.3 years (range 5–40 years) and the average follow‐up was 6.5 years (range 1–10 years). There were 66 good results, 14 fair and eight poor. There were no complications. In the group of major orthopaedic procedures, the average age of the 10 patients was 32.5 years (range 27–40 years), and the average follow‐up was 2.3 years (range 1–5 years). There were 16 good results, one fair and three poor. Postoperative bleeding complications occurred in three of the 20 major orthopaedic procedures performed (15% complications rate). They occurred in three patients treated with insufficient doses of recombinant activated factor VII. Despite such complications, the study has shown that haemophilic patients with inhibitors requiring elective orthopaedic surgery (EOS) can undergo such procedures with a high expectation of success. In other words, EOS is now possible in haemophilic patients with inhibitors, leading to an improved quality of life for these patients. Thorough analysis of each case as part of a multidisciplinary team will allow us to perform elective orthopaedic procedures in patients with inhibitors.Keywords
This publication has 22 references indexed in Scilit:
- Joint Surgery in Patients with InhibitorsPublished by Wiley ,2003
- Orthopaedic Surgery in Haemophilic Patients with Inhibitors: A Review of the LiteraturePublished by Wiley ,2000
- Management of haemophilia in patients with high‐titre inhibitors: focus on the evolution of activated prothrombin complex concentrate AUTOPLEX® THaemophilia, 1999
- Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in haemophilia patients with inhibitorsHaemophilia, 1999
- Immune Tolerance for the Treatment of Factor VIII Inhibitors ‐ Twenty Years' ‘Bonn Protocol’Vox Sanguinis, 1996
- Successful Hemostasis During a Major Orthopedic Operation by Using Recombinant Activated Factor VII in a Patient With Severe Hemophilia A and a Potent InhibitorMayo Clinic Proceedings, 1994
- Efficacy and safety of vapor‐heated anti‐inhibitor coagulant complex in hemophilia patients. FEIBA Study GroupTransfusion, 1990
- The Use of Porcine Factor VIII Concentrate (Hyate:C) in the Treatment of Patients With Inhibitor Antibodies to Factor VIIIArchives of internal medicine (1960), 1989
- Porcine factor VIII and plasmapheresis in the management of hemophiliac patients with inhibitorsAmerican Journal of Hematology, 1986
- Use of activated prothrombin complex concentrate overmultiple surgical episodes in a hemophilic child with an inhibitorThe Journal of Pediatrics, 1983